Law360 interviewed Peter Goss on the recent sanctions ruling in the ACTOS multidistrict litigation, and in that context Goss discussed the real-world challenges that global companies face in complying with the e-discovery standards and expectations of U.S. Courts. Goss highlighted the difficulty presented by 30(b)(6) deposition notices on e-discovery topics, since most companies will not have an employee who can speak to decisions made by IT departments in other countries. The article is available to Law360 subscribers here.
Mr. Goss focuses his national practice on pharmaceutical and medical device product liability litigation and toxic torts. He has represented major pharmaceutical, medical technology, and chemical firms in hundreds of cases. Mr. Goss, who has won several published Daubert decisions, often serves as “science counsel” in life sciences litigation. He collaborates with leading experts to present complex medical and scientific evidence, both in dispositive motions and at trial. He is a frequent commentator on scientific evidence and legal developments of interest to FDA-regulated industries.
Blackwell Burke P.A., a litigation and trial boutique in Minneapolis, Minnesota, serves as national trial and litigation counsel for numerous Fortune 500 companies. The firm has extensive experience in class action defense, commercial litigation, food industry defense, labor and employment, and products liability. The firm has represented corporate clients in practically every jurisdiction in the country, as well as several foreign countries.